Reproducibility Study of Over Active Bladder Symptom Score [OABSS]

A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

NCT01317810 ·Status: WITHDRAWN

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345 ·Status: TERMINATED

A Study of YM178 in Patients With Symptomatic Overactive Bladder

NCT00527033 ·Status: COMPLETED ·Phase: PHASE2

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

NCT04562090 ·Status: COMPLETED ·Phase: PHASE4

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

NCT03903094 ·Status: COMPLETED

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

NCT03602508 ·Status: COMPLETED

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214 ·Status: COMPLETED ·Phase: PHASE4

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231 ·Status: COMPLETED

Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects

NCT01029015 ·Status: COMPLETED

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688 ·Status: COMPLETED ·Phase: PHASE3

A Cross-sectional Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS)

NCT02618421 ·Status: COMPLETED

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02320773 ·Status: COMPLETED

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00689104 ·Status: COMPLETED ·Phase: PHASE3

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

NCT00658684 ·Status: COMPLETED ·Phase: PHASE3

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072 ·Status: COMPLETED

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment

NCT01318837 ·Status: COMPLETED ·Phase: PHASE4

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964 ·Status: COMPLETED ·Phase: PHASE3

A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

NCT00189800 ·Status: COMPLETED ·Phase: PHASE3

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

NCT00966004 ·Status: COMPLETED ·Phase: PHASE3

Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial

NCT05157295 ·Status: UNKNOWN ·Phase: PHASE4

Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women

NCT03807024 ·Status: COMPLETED

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01604928 ·Status: COMPLETED ·Phase: PHASE2

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome

NCT00239317 ·Status: COMPLETED ·Phase: PHASE3